Grifols Biologicals LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$10.9M
Doctors Paid
28
Transactions
1,775
2024 Total
$33,449
Payment Breakdown by Category
Research$10.8M (98.7%)
Travel$116,026 (1.1%)
Consulting$22,863 (0.2%)
Food & Beverage$1,479 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.8M | 1,642 | 98.7% |
| Travel and Lodging | $116,026 | 102 | 1.1% |
| Consulting Fee | $22,863 | 10 | 0.2% |
| Food and Beverage | $1,479 | 20 | 0.0% |
| Honoraria | $1,462 | 1 | 0.0% |
Payments by Type
Research
$10.8M
1,642 transactions
General
$141,830
133 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis With Infusion of Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate AD | $5.7M | 0 | 379 |
| Pilot Study to Evaluate the Efficacy and Safety of Plasma Exchange With Albutein 5 in Patients With Amyotrophic Lateral Sclerosis | $1.2M | 0 | 17 |
| A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, ParallelGroup Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous Human Flebogamma 5 DIF in Patients With Post-Polio Syndrome | $881,620 | 0 | 508 |
| A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects and LoadingMaintenance Dosing in Treatment-Nave Subjects With Primary Immunodeficiency | $778,194 | 2 | 156 |
| A Prospective, Randomized, Active-Controlled, Single-blind, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols FS Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Subjects | $572,432 | 1 | 84 |
| An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20 Administered for 6 Months in Subjects With Primary Immunodeficiency | $379,581 | 1 | 95 |
| A Multi-Center, Single-Dose and Repeat-Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety and Tolerability as Well as Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous Human 15 Administered Subcutaneousl | $290,650 | 0 | 64 |
| A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous Human Flebogamma 5 DIF in Patients With Post-Polio Syndrome | $213,002 | 0 | 52 |
| A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols FS Grifols as an Adjunct to Hemostasis During Parenchymous Tissue Open Surgeries | $148,690 | 0 | 37 |
| Prevention of Mortality With Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites | $102,369 | 0 | 76 |
| A Multi-Center, Parallel, Double-Blinded, PlaceboControlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY plus Standard Medical Treatment Compared to Placebo plus Standard Medical Treatment to Prevent Infections in Patients with Hypogammaglobulinemia and RecurrentorSevereInfections Associated with B-cell Chronic Lymphocytic Leukemia | $88,279 | 0 | 3 |
| A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naive Subjects With Primary Immunodeficiency | $72,548 | 0 | 19 |
| A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols FS Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery | $64,313 | 0 | 20 |
| Effects of Plasma Exchange With Human Serum Albumin 5 PE-A 5 on Short-term Survival in Subjects With Acute-On-Chronic Liver Failure ACLF at High Risk of Hospital Mortality | $62,804 | 0 | 34 |
| A Prospective, Randomized, Active-Controlled, Single-blind, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Haemostasis During Surgery in Paediatric Subjects | $34,864 | 0 | 4 |
| A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of PlasmaDerived Factor VIIIVWF Alphanate in Immune Tolerance Induction Therapy in Subjects with Congenital Hemophilia A | $30,829 | 0 | 2 |
| A Multicenter, Randomized, Cross-over, Open-label Study to Evaluate IGSC 20 Flexible Dosing Including Daily Push Dosing In Treatment-Experienced Subjects With Primary Immunodeficiency PI and Evaluation of LoadingMaintenance IGSC 20 in Treatment-Nave | $30,000 | 1 | 10 |
| Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality. | $26,285 | 0 | 11 |
| A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, ParallelGroup Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous Human Flebogamma 5percent DIF in Patients With Post-Polio Syndrome | $19,868 | 0 | 17 |
| A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY plus Standard Medical Treatment Compared to Placebo plus Standard Medical Treatment to Prevent Infections in Patients with Hypogammaglobulinemia and Recurrent or Severe Infections Associated with Bcell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma | $18,393 | 0 | 1 |
| A Multicenter, Randomized, Cross-over, Open-label Study to Evaluate IGSC 20 Flexible Dosing Including Daily Push Dosing In Treatment-Experienced Subjects With Primary Immunodeficiency PI and Evaluation of LoadingMaintenance IGSC 20 in Treatment-Nave Subjects With PI | $17,880 | 0 | 8 |
| Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With 'Acute-On-Chronic Liver Failure' (ACLF) at High Risk of Hospital Mortality. | $15,056 | 0 | 10 |
| A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel?Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma 5% DIF in Patients With Post-Polio Syndrome | $8,945 | 0 | 5 |
| A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols FS Grifols as an Adjunct to Hemostasis During Soft Tissue Open Surgeries | $7,715 | 0 | 4 |
| A Multi-center, Single-Sequexperienced Subjects and Loading/Mance, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Eintenance Dosing in Treatment-Naive Subjects With Primary Immunodeficiency | $6,628 | 0 | 1 |
| A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin IGIV3I Grifols 10 in Patients With Idiopathic Immune Thrombocytopenic Purpura | $5,132 | 0 | 1 |
| Multicenter, Prospective, Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen FIB Grifols in Patients with Congenital Afibrinogenaemia | $4,450 | 0 | 5 |
| A Post-marketing Observation Study to Assess the Efficacy and Safety of the FVIIIVWF Complex Human, AlphanateR, in Preventing Excessive Bleeding During Surgery in Subjects With Congenital Type 3 Von Willebrand Disease | $3,000 | 0 | 1 |
| A Phase IIIII Pivotal Trial Evaluating the Safety, Pharmacokinetic Properties and Efficacy of a Plasma-Derived Anti-thrombin III Concentrate With Administration in Surgery, Pregnancy and Thromboembolic or Thrombotic Events. | $2,000 | 0 | 1 |
| A Prospective, Randomized, Double-blind, Phase II Study to Evaluate the Safety and Efficacy of Topical Thrombin Human Grifols as an Adjunct to Hemostasis During Vascular, Hepatic, Soft Tissue, and Spinal Open Surgeries | $500.00 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Specialist | $217,587 | 6 | $36,265 |
| Allergy | $33,290 | 1 | $33,290 |
| Neurology | $16,840 | 2 | $8,420 |
| Rheumatology | $14,334 | 1 | $14,334 |
| Blood Banking & Transfusion Medicine | $11,907 | 1 | $11,907 |
| Gastroenterology | $11,297 | 3 | $3,766 |
| Transplant Surgery | $8,788 | 1 | $8,788 |
| Nephrology | $7,898 | 2 | $3,949 |
| Hepatology | $5,573 | 1 | $5,573 |
| Critical Care Medicine | $3,253 | 1 | $3,253 |
| Internal Medicine | $2,810 | 2 | $1,405 |
| Geriatric Medicine | $2,221 | 3 | $740.45 |
| Neurological Surgery | $824.66 | 1 | $824.66 |
| Psychiatry | $747.98 | 1 | $747.98 |
| Geriatric Psychiatry | $482.92 | 1 | $482.92 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. William Lumry, M.d, M.D | Specialist | Dallas, TX | $162,736 | $0 |
| Dr. Oscar Lopez, Md, MD | Specialist | Pittsburgh, PA | $52,756 | $0 |
| Martha Tarpay, Md, MD | Allergy | Oklahoma City, OK | $33,290 | $0 |
| Jeffrey Cummings, Md, MD | Neurology | Los Angeles, CA | $16,315 | $0 |
| Anna Koo, Md, MD | Rheumatology | Cleveland, OH | $14,334 | $0 |
| Unknown Provider | — | — | $14,000 | $0 |
| Dr. Zbigniew Szczepiorkowski, Md, Phd, MD, PHD | Blood Banking & Transfusion Medicine | Lebanon, NH | $11,907 | $0 |
| Meelie Debroy, Md, MD | Transplant Surgery | Valhalla, NY | $8,788 | $0 |
| Dr. Jasmohan Bajaj, Md, MD | Gastroenterology | Richmond, VA | $5,724 | $0 |
| Prof. Tarek Hassanein, M.d, M.D | Hepatology | Coronado, CA | $5,573 | $0 |
| Nilang Patel, M.d, M.D | Nephrology | Richmond, VA | $5,408 | $0 |
| Ethan Weinberg | Gastroenterology | Philadelphia, PA | $3,520 | $0 |
| Ram Subramanian, M.d, M.D | Critical Care Medicine | Atlanta, GA | $3,253 | $0 |
| John Videen, Md, MD | Nephrology | Chula Vista, CA | $2,490 | $0 |
| Nikolaos Pyrsopoulos, Md,Phd,Mba, MD,PHD,MBA | Gastroenterology | New York, NY | $2,053 | $0 |
| Dobri Kiprov, Md., P.c, MD., P.C | Internal Medicine | San Francisco, CA | $1,987 | $0 |
| Dr. Angela Pedraza, M.d, M.D | Specialist | West Palm Beach, FL | $981.95 | $0 |
| Dr. Alireza Atri, Md Phd, MD PHD | Neurological Surgery | Boston, MA | $824.66 | $0 |
| Dr. Kimball Johnson, Md, MD | Internal Medicine | Atlanta, GA | $823.28 | $0 |
| Dr. Babak Tousi, M.d, M.D | Geriatric Medicine | Cleveland, OH | $787.73 | $0 |
| Jacobo Mintzer, Md, MD | Psychiatry | Charleston, SC | $747.98 | $0 |
| Dr. Joshua Shua-Haim, M.d, M.D | Geriatric Medicine | Manchester, NJ | $746.71 | $0 |
| Thomas Obisesan, Md, MD | Geriatric Medicine | Washington, DC | $686.92 | $0 |
| Dr. Jose Delagandara, M.d, M.D | Specialist | West Palm Beach, FL | $562.57 | $0 |
| David Geldmacher | Neurology | Birmingham, AL | $525.00 | $0 |
Ad
Top Products
- Flebogamma DIF $5.0M
- Albutein $3.2M
Associated Products (4)
- Flebogamma DIF $5.5M
- Fibrin Sealant $507,871
- Flebogamma $99,972
- VistaSeal $86,645
Payment Categories
- Food & Beverage $1,479
- Consulting $22,863
- Travel & Lodging $116,026
- Research $10.8M
About Grifols Biologicals LLC
Grifols Biologicals LLC has made $10.9M in payments to 28 healthcare providers, recorded across 1,775 transactions in the CMS Open Payments database. In 2024, the company paid $33,449. The top product by payment volume is Flebogamma DIF ($5.0M).
Payments were distributed across 15 medical specialties. The top specialty by payment amount is Specialist ($217,587 to 6 doctors).
Payment categories include: Food & Beverage ($1,479), Consulting ($22,863), Research ($10.8M), Travel & Lodging ($116,026).
Grifols Biologicals LLC is associated with 4 products in the CMS Open Payments database, including Flebogamma DIF, Fibrin Sealant, and Flebogamma.